[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551688":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":215,"collaborators":20,"id":217,"slug":218,"hasResults":219,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":20,"eligibilityCriteria":223,"healthyVolunteers":219,"sex":224,"minAge":225,"maxAge":20,"enrollmentInfo":226,"targetDuration":20,"studyType":229,"phases":230,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":246},{"fullName":5,"class":6},"Schrödinger, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","28-day treatment cycle.",[13],"Drug: SGR-3515",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","SGR-3515","SGR-3515 will be administered orally with an intermittent schedule.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Margaret Dugan, MD","CMO\u002FStudy Physician","STUDY_DIRECTOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Study Physician","CONTACT","+15032991150","sdgr-trials-group@schrodinger.com",[33,51,64,77,89,101,114,127,139,152,165,174,187,200],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Yale University, Yale Cancer Center","RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-72.92816,41.30815,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":20,"phoneExt":20,"email":20},"Patricia LoRusso, DO","PRINCIPAL_INVESTIGATOR",{"facility":52,"status":35,"city":53,"state":54,"zip":55,"country":39,"countryCode":40,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Northwestern University","Chicago","Illinois","60611",{"type":42,"coordinates":57},[58,59],-87.65005,41.85003,{"lat":59,"lon":58},[62],{"name":63,"role":50,"phone":20,"phoneExt":20,"email":20},"Pedro de Viveiros, MD",{"facility":65,"status":35,"city":66,"state":67,"zip":68,"country":39,"countryCode":40,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"University of Michigan","Ann Arbor","Michigan","48109",{"type":42,"coordinates":70},[71,72],-83.74088,42.27756,{"lat":72,"lon":71},[75],{"name":76,"role":50,"phone":20,"phoneExt":20,"email":20},"Jean Siedel, DO",{"facility":78,"status":35,"city":79,"state":67,"zip":80,"country":39,"countryCode":40,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Karmanos Cancer Institute","Detroit","48201",{"type":42,"coordinates":82},[83,84],-83.04575,42.33143,{"lat":84,"lon":83},[87],{"name":88,"role":50,"phone":20,"phoneExt":20,"email":20},"Ira Winer, MD",{"facility":90,"status":35,"city":91,"state":91,"zip":92,"country":39,"countryCode":40,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Icahn School of Medicine at Mount Sinai","New York","10029",{"type":42,"coordinates":94},[95,96],-74.00597,40.71427,{"lat":96,"lon":95},[99],{"name":100,"role":50,"phone":20,"phoneExt":20,"email":20},"Deborah Doroshow, MD",{"facility":102,"status":35,"city":103,"state":104,"zip":105,"country":39,"countryCode":40,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":42,"coordinates":107},[108,109],-80.84313,35.22709,{"lat":109,"lon":108},[112],{"name":113,"role":50,"phone":20,"phoneExt":20,"email":20},"Robert W Naumann, MD",{"facility":115,"status":35,"city":116,"state":117,"zip":118,"country":39,"countryCode":40,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"University of Cincinnati Medical Center","Cincinnati","Ohio","45267",{"type":42,"coordinates":120},[121,122],-84.51439,39.12711,{"lat":122,"lon":121},[125],{"name":126,"role":50,"phone":20,"phoneExt":20,"email":20},"Amanda Jackson, MD",{"facility":128,"status":35,"city":129,"state":117,"zip":130,"country":39,"countryCode":40,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Ohio State University","Columbus","43210",{"type":42,"coordinates":132},[133,134],-82.99879,39.96118,{"lat":134,"lon":133},[137],{"name":138,"role":50,"phone":20,"phoneExt":20,"email":20},"John Hays, MD",{"facility":140,"status":35,"city":141,"state":142,"zip":143,"country":39,"countryCode":40,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Stephenson Cancer Center","Oklahoma City","Oklahoma","73104",{"type":42,"coordinates":145},[146,147],-97.51643,35.46756,{"lat":147,"lon":146},[150],{"name":151,"role":50,"phone":20,"phoneExt":20,"email":20},"Kathleen N Moore, MD",{"facility":153,"status":35,"city":154,"state":155,"zip":156,"country":39,"countryCode":40,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":42,"coordinates":158},[159,160],-86.78444,36.16589,{"lat":160,"lon":159},[163],{"name":164,"role":50,"phone":20,"phoneExt":20,"email":20},"Vivek Subbiah, MD",{"facility":166,"status":35,"city":154,"state":155,"zip":167,"country":39,"countryCode":40,"cosmosGeoPoint":168,"geoPoint":170,"contacts":171},"Vanderbilt-Ingram Cancer Center\u002FHenry-Joyce Cancer Clinic","37232",{"type":42,"coordinates":169},[159,160],{"lat":160,"lon":159},[172],{"name":173,"role":50,"phone":20,"phoneExt":20,"email":20},"Michael K Gibson, MD",{"facility":175,"status":35,"city":176,"state":177,"zip":178,"country":39,"countryCode":40,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"University of Texas Southwestern","Dallas","Texas","75235",{"type":42,"coordinates":180},[181,182],-96.80667,32.78306,{"lat":182,"lon":181},[185],{"name":186,"role":50,"phone":20,"phoneExt":20,"email":20},"David Miller, MD",{"facility":188,"status":35,"city":189,"state":190,"zip":191,"country":39,"countryCode":40,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"NEXT Virginia","Fairfax","Virginia","22031",{"type":42,"coordinates":193},[194,195],-77.30637,38.84622,{"lat":195,"lon":194},[198],{"name":199,"role":50,"phone":20,"phoneExt":20,"email":20},"Mohamad A Salkeni, MD",{"facility":201,"status":35,"city":202,"state":203,"zip":204,"country":205,"countryCode":206,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Princess Margaret Cancer Centre","Toronto","Ontario","MSG 1X6","Canada","CA",{"type":42,"coordinates":208},[209,210],-79.39864,43.70643,{"lat":210,"lon":209},[213],{"name":214,"role":50,"phone":20,"phoneExt":20,"email":20},"Stephanie Lheureux, MD",{"type":216,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100551688","phase-1-study-of-sgr-3515-in-participants-with-advanced-solid-tumors-100551688",false,"NCT06463340","Study of SGR-3515 In Participants With Advanced Solid Tumors.","A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors.","Inclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor\n* Measurable disease per RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participant must understand and sign an Informed Consent Form (ICF) prior to any study-related assessments\u002Fprocedures\n* Adequate bone marrow and organ function\n* Women of child-bearing potential (WOCBP) or males must agree to use highly effective contraception for the duration of study and for 90 days after the last dose of study drug\n\nExclusion Criteria\n\n* Participants with primary Central Nervous System (CNS tumors).\n* Participant has received prior systemic anti-cancer treatments or other investigational agents ≤ 21 days of first dose of study drug, or 5 half-lives, whichever is shorter\n* Participant who has received definitive local control radiation (any dose greater than 50 Gy) \\\u003C 42 days prior to the first dose of study drug.\n* Participant who has received major surgeries ≤ 21 days prior to first dose of study drug\n* Participants who have not recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade 2 alopecia, peripheral neuropathy and ototoxicity.\n* Participant who has another clinically significant invasive malignancy, as determined by the investigator, ≤ 2 years prior to the first dose","ALL","18 Years",{"count":227,"type":228},52,"ESTIMATED","INTERVENTIONAL",[231],"PHASE1","The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.",[234],"Advanced Solid Tumor",[236,234],"Solid Tumor","2025-07-29",{"date":239,"type":240},"2025-08-01","ACTUAL",{"date":242,"type":240},"2024-06-18",{"date":244,"type":228},"2026-12-31",{"name":5,"class":6},14]